Clinical Trial: Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07673900) titled 'Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants' on June 21.

Brief Summary: VX-201-101 is a first-in-human Phase 1 clinical study evaluating VX-201, a needle-free microneedle (MN) array patch (MAP) that delivers semaglutide through the skin as an alternative to subcutaneous (SC) injection.

Study Start Date: June 15

Study Type: INTERVENTIONAL

Condition: Overweight and/or Obesity

Intervention: COMBINATION_PRODUCT: VX-201

VX-201 is a needle free, shelf-stable, microneedle array patch (MAP) for delivery of semaglutide epi/intra-de...